E Fund Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

E Fund Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$528K	Sell	4,751 -1,702	-26%	-$154K	0.01%	251
2026 Q1	$561K	Buy	+6,453	New	+$628K	0.02%	271
2025 Q2	$364K	Buy	5,761 +365	+7%	+$22.3K	0.02%	273
2025 Q1	$286K	Buy	+5,396	New	+$299K	0.01%	321
2024 Q4	–	Sell	-4,149	Closed	-$217K	–	409
2024 Q3	$217K	Buy	+4,149	New	+$199K	0.01%	312
2024 Q2	–	Sell	-10,333	Closed	-$448K	–	368
2024 Q1	$448K	Buy	10,333 +3,800	+58%	+$166K	0.03%	175
2023 Q4	$300K	Buy	+6,533	New	+$206K	0.02%	230
2023 Q3	–	Sell	-13,948	Closed	-$230K	–	316
2023 Q2	$230K	Sell	13,948 -536	-4%	-$9.68K	0.02%	261
2023 Q1	$258K	Sell	14,484 -1,572	-10%	-$39.5K	0.02%	256
2022 Q4	$468K	Sell	16,056 -1,979	-11%	-$50.9K	0.04%	140
2022 Q3	$442K	Buy	+18,035	New	+$335K	0.04%	156

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

E Fund Management's RYTM Position: Q2 2026 in Review

E Fund Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 26% in Q2 2026, selling an estimated $154K and leaving 4,751 shares worth $528K. The position accounts for 0.01% of the portfolio, ranked #251.

E Fund Management first reported a position in RYTM in Q3 2022 and has held it in 11 quarters since. The position peaked at $561K in Q1 2026. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

E Fund Management held 4,751 shares of Rhythm Pharmaceuticals worth $528K as of Q2 2026.
E Fund Management sold 1,702 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $154K.
Rhythm Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2026, its #251 holding.
E Fund Management first reported a position in Rhythm Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
E Fund Management's Rhythm Pharmaceuticals position peaked at $561K in Q1 2026.
302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.